
Development and validation of a mass spectrometric method to determine the identity of rituximab based on its microheterogeneity profile. IN PRESS

Development and validation of a mass spectrometric method to determine the identity of rituximab based on its microheterogeneity profile. IN PRESS
Validation of an ADCC assay using human primary natural killer cells to evaluate biotherapeutic products bearing an Fc región....
Validation of a cell proliferation assay to assess the potency of a Dialyzable Leucocyte Extract intended for batch release....
Regulatory Pathway for Licensing Biotherapeutics in Mexico. VER MÁS
Transcriptome-based identification of lovastatin as a breast cancer stem cell-targeting drug. VER MÁS
Development and validation of a bioassay to evaluate binding of adalimumab to cell membrane-anchored TNFα using flow cytometry detection....
ALTHEA Gold Libraries™: antibody libraries for therapeutic antibody discovery. VER MÁS
Fecha de publicación: 6 de septiembre de 2022 In Vitro and In Vivo Characterization of a Broadly Neutralizing Anti-SARS-CoV-2...
Sequencing Analysis and Identification of the Primary Peptide Component of the Dialyzable Leukocyte Extract “Transferon Oral”: The Starting Point...

+52 (55) 5729 6000 Ext. 62543
Escuela Nacional de Ciencias Biológicas. Prolongación de Carpio y Plan de Ayala S/N, Del. Miguel Hidalgo, CDMX, C.P. 11340.
©2026 UDIBI